The announcement follows Affimed’s listing transfer to the Nasdaq Capital Market in October 2023, which was seen as a strategic move to unlock new growth opportunities. The transfer, effective from October 4, 2023, allows Affimed to be among a broader range of growth-oriented businesses, providing increased visibility and accessibility to institutional and retail investors.
Affimed N.V. Sells Wholly-Owned Subsidiary AbCheck and Works Towards Growth Opportunities in Cancer Immunotherapy
Published |
Modified
CSIMarket Newsroom | CSIMarket.com
CSIMarket Newsroom | CSIMarket.com
Source for this article: Based on ’s official statement
For details on how CSIMarket validates financial and corporate news, please review our
Editorial Standards & Fact-Checking Policy
.
Comments